Email this article Effects of the long-acting garlic tablets "Allicor" on the incidence of acute respiratory viral infections in children
- Authors: Andrianova IV1, Sobenin IA1, Sereda EV1, Borodina LI1, Studenikin MI1
-
Affiliations:
- Issue: Vol 78, No 3 (2003)
- Pages: 53-56
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29349
- ID: 29349
Cite item
Full Text
Abstract
Aim. To elucidate the prospects administration of allicor (long-releasing garlic tablets) in prevention of acute respiratory diseases (ARD) in children vs benzimidazole (dibazole).
Material and methods. At the first stage, tolerance of allicor (600 mg/day) and its effects on ARD morbidity were investigated in an opened 5-month study in 172 children aged 7-16 years compared to 468 controls. As the second stage, the effects of allicor (300 mg/day) on ASRD morbidity were investigated in a double-blind placebo-controlled randomized 5-month trial in 42 children aged 10-12 years in comparison with 41 placebo-treated children and 73 benzimidazole-treated children. Results. At the first stage of the study allicor was not observed to induce gastrointestinal side effects in children at any dosage while ARD morbidity was reduced 2-4-fold as compared to the controls. At the second stage of the study allicor reduced ARD morbidity 1.7-fold compared to placebo and 2.4-fold vs benzimidazole. There was no significant difference in ARD morbidity between placebo- and benzimidazole-treated groups. Health index in allicor-treated group was 1.5-fold higher as compared either to placebo- or benzimidazole-treated children.
Conclusion. Thus, the results of this study have demonstrated that allicor is effective for non-specific prevention of acute respiratory infections in children and has no side effects. ARD prevention with benzimidazole appeared ineffective in placebo-controlled study, so the development of new useful and safe preparations is of ultimate importance.
Material and methods. At the first stage, tolerance of allicor (600 mg/day) and its effects on ARD morbidity were investigated in an opened 5-month study in 172 children aged 7-16 years compared to 468 controls. As the second stage, the effects of allicor (300 mg/day) on ASRD morbidity were investigated in a double-blind placebo-controlled randomized 5-month trial in 42 children aged 10-12 years in comparison with 41 placebo-treated children and 73 benzimidazole-treated children. Results. At the first stage of the study allicor was not observed to induce gastrointestinal side effects in children at any dosage while ARD morbidity was reduced 2-4-fold as compared to the controls. At the second stage of the study allicor reduced ARD morbidity 1.7-fold compared to placebo and 2.4-fold vs benzimidazole. There was no significant difference in ARD morbidity between placebo- and benzimidazole-treated groups. Health index in allicor-treated group was 1.5-fold higher as compared either to placebo- or benzimidazole-treated children.
Conclusion. Thus, the results of this study have demonstrated that allicor is effective for non-specific prevention of acute respiratory infections in children and has no side effects. ARD prevention with benzimidazole appeared ineffective in placebo-controlled study, so the development of new useful and safe preparations is of ultimate importance.
References
- A declaration on the promotion of patients rights in Europe. WHO, Regional Office for Europe; 1994.
- Стефани Д. В., Вельтищев Ю. Е. Иммунология и иммунопатология детского возраста. М.: Медицина; 1996.
- Российский Д. М. Чеснок (Allium sativum) и его клиническое применение. Клин. мед. 1933; 5-6: 315-317.
- Орехов А. Н., Тертое В. В., Собенин И. А. и др. Прямое антиатерогенное действие чеснока. Бюл. экспер. биол. 1996; 6: 695-697.
- Андрианова И. В., Габбасов 3. А., Ионова В. Г. и др. Влияние чесночных таблеток алликор на агрегацию тромбоцитов in vivo и in vitro. Там же. 1997; 7: 97-100.
- Марголина М. И. Опыт лечения нагноительных процессов в легких фитонцидами чеснока. Врач, дело 1948; 8: 727.
- Булатов Р. К., Злидников Д. М., Федосеев П. Б. и др. Применение фитонцидов чеснока для лечения больных с различными воспалительными заболеваниями органов дыхания. Сов. мед. 1965; 28 (1): 86-90.
- Dankert J., Tromp Т. F., de-Vries H. et al. Antimicrobial activity of crude juices of Allium ascalonicum, Allium cera and Allium sativum. Z. Bakteriol. Orig. A. 1979; 245: 229-239.
- Воробьева А. Д. Рефлекторная терапия. М.; Л.: Медицина; 1957.
- Nagai К. Effect of garlic extract in prevention of virus infections. Kansenshogaku Zasshi 1973; 47 (4): 111-115.
- Esanu V., Prahoveanu E. The effect of garlic extract, applied as such or in association with NaF, on experimental influenza in mice. Virologie 1983; 34 (1): 11-15.
- Сорокин А. М., Пушников А. А., Кольцов В. Д. Влияние производных бензимидазола на вирусную инфекцию. Вопр. вирусол. 1976; 2: 206-211.
- Szram S., Denys A. Effects of benzimidazole on the development of organ lesions in experimental influenza virus infection in mice. Med. Dosw. Mikrobiol. 1972; 24 (1): 55-57.
- Шапошников И. В., Яковлева Р. И., Черезова Л. М. и др. Методы неспецифической профилактики гриппа и других острых респираторных заболеваний дибазолом и аскорбиновой кислотой. Вопр. вирусол. 1976; 4: 429-431.
- Ершов Ф. И., Григориан С. С., Семоненко Т. А. и др. Журн. микробиол. 1991; 10: 42-45.
Supplementary files
